Lutetium-177 DOTATATE: A Practical Review

Angela Y. Jia, Rojano Kashani, Nicholas G. Zaorsky, Daniel E. Spratt, Ana P. Kiess, Jeff M. Michalski, Jacqueline E. Zoberi, Hyun Kim, Brian C. Baumann

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate in endocrine tissues throughout the body. Though most are indolent, clinical outcomes vary greatly based on histologic differentiation and grade. Peptide receptor radionuclide therapy has emerged as a promising treatment for patients with locally advanced and/or metastatic disease refractory to standard of care treatment. The phase III NETTER-1 trial found that [177Lu] Lu-DOTA-[Tyr3]-octreotate improved disease-free survival versus octreotide alone for somatostatin receptor-positive gastroenteropancreatic NETs and had a favorable toxicity profile, leading to Food and Drug Administration approval. [177Lu] Lu-DOTA-[Tyr3]-octreotate is an important new treatment that expands the role of radiation in the treatment of NETs. Several important trials are ongoing to better elucidate the role of this treatment.

Original languageEnglish
Pages (from-to)305-311
Number of pages7
JournalPractical Radiation Oncology
Issue number4
StatePublished - Jul 1 2022


Dive into the research topics of 'Lutetium-177 DOTATATE: A Practical Review'. Together they form a unique fingerprint.

Cite this